<DOC>
	<DOCNO>NCT00000825</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability give IL-2 plus anti-HIV ( antiretroviral ) therapy HIV-positive patient CD4 cell count ( cell immune system fight infection ) least 350 cells/mm3 . This study also examine ability antiretroviral therapy combine IL-2 boost immune system . IL-2 , give injection skin , combination anti-HIV therapy increase CD4 cell count . This study examine 3 dos IL-2 order determine safest effective dose use .</brief_summary>
	<brief_title>The Effects Giving Interleukin-2 ( IL-2 ) Plus Anti-HIV Therapy HIV-Positive Patients With CD4 Cell Counts Least 350 Cells/mm3</brief_title>
	<detailed_description>IL-2 , administer subcutaneously combination antiretrovirals , result increase CD4+ cell count may retard HIV disease progression . Using small patient sampling , Phase II study help develop clinical experience need consider formation large , complete Phase III trial . Seventy-two HIV-infected patient ( previously treat naive ) randomize independently receive either control therapy antiretrovirals alone OR escalate dos subcutaneous interleukin-2 ( IL-2 ) plus antiretrovirals . In absence dose-limiting toxicity ( DLT ) least 9 12 patient Group 1 , 12 additional patient enter Group 2 treat indicate . In absence DLT 9 12 patient Group 2 , final 12 patient enter Group 3 . Those patient enrol either first 2 dose group complete 3 course therapy dose escalate maximum dose . A course treatment define 5 day IL-2 plus antiretrovirals follow 7 week antiretroviral therapy alone .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have CD4 cell count great equal 300 cells/mm3 . Have AIDSdefining illness . Are least 18 year old . Have antiretroviral therapy least 7 day prior study entry . Exclusion Criteria Patients eligible study : Abuse alcohol drug , serious psychiatric medical illness would affect safety ability complete study . Have history following : cancer ( Kaposi 's sarcoma ) , AIDSdefining illness , central nervous system abnormality , autoimmune/inflammatory disease . Are pregnant breastfeeding . Have ever receive IL2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>DNA , Viral</keyword>
</DOC>